Breaking Down SG&A Expenses: Jazz Pharmaceuticals plc vs Alpine Immune Sciences, Inc.

SG&A Expenses: Jazz vs. Alpine - A Decade of Financial Strategy

__timestampAlpine Immune Sciences, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20142287709406114000
Thursday, January 1, 20156844000449119000
Friday, January 1, 20168586000502892000
Sunday, January 1, 20176079000544156000
Monday, January 1, 20188362000683530000
Tuesday, January 1, 20199467000736942000
Wednesday, January 1, 202010899000854233000
Friday, January 1, 2021145600001451683000
Saturday, January 1, 2022179680001416967000
Sunday, January 1, 2023222220001343105000
Loading chart...

Unleashing insights

A Comparative Analysis of SG&A Expenses: Jazz Pharmaceuticals vs. Alpine Immune Sciences

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Jazz Pharmaceuticals and Alpine Immune Sciences, two prominent companies, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Jazz Pharmaceuticals consistently reported higher SG&A expenses, peaking at approximately $1.45 billion in 2021. This represents a staggering 3,500% increase compared to Alpine Immune Sciences' highest expense of around $22 million in 2023. Alpine, while smaller in scale, has shown a steady growth in its SG&A expenses, nearly doubling from 2014 to 2023. This data not only highlights the scale of operations but also reflects strategic investments in marketing and administration. As the industry evolves, these financial insights provide a window into the operational priorities of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025